CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

CAR T cells
Delivery of Oncolytic Immunotherapy by MSCs Enhances CAR-T Cell Anti-Tumor Activity
Delivery of Oncolytic Immunotherapy by MSCs Enhances CAR-T Cell Anti-Tumor Activity
The Scientist Creative Services Team in Collaboration with IsoPlexis | Apr 5, 2021
Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.
Bispecific Antibodies Treat Cancer in Mouse Models
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena | Mar 5, 2021
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
Immunotherapy Combo Reduces Solid Tumors in Mice
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
Live-cell Imaging
Live-cell Imaging
The Scientist Creative Services Team | Aug 27, 2020
Download this eBook to take a closer look at past efforts, modern challenges, and future advances!
Adoptive Cell Therapy Summit
Adoptive Cell Therapy Summit
The Scientist Creative Services Team | Aug 24, 2020
Join us to learn about adoptive cell therapies from leading experts in the field of cancer immunology. 
Natural Killer Cell Therapies Catch Up to CAR T
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020
There’s a new cell-based cancer immunotherapy on the block.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
Amy Schleunes | Mar 24, 2020
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
Ashley Yeager | Feb 6, 2020
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Kerry Grens | Jan 20, 2020
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.